According to the semi-annual report for 2024 released by Luoxin Pharmaceuticals Group Stock (002793.SZ), the company achieved revenue of 1.259 billion yuan, a year-on-year increase of 0.30%. The net loss attributable to shareholders of the listed company was 88.7099 million yuan, and the net loss after deducting non-recurring gains and losses attributable to shareholders of the listed company was 0.108 billion yuan. The basic loss per share was 0.08 yuan.